Antigua and Barbuda vs North Macedonia: Hepatitis B surface antigen (HBsAg) prevalence
Antigua and Barbuda
0.2%
in 2024
North Macedonia
0.2%
in 2024
Antigua and Barbuda rank
82nd
North Macedonia rank
82nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Antigua and Barbuda
- North Macedonia
How they compare
Antigua and Barbuda currently reports 0.2% against 0.2% in North Macedonia, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Antigua and Barbuda ahead.
Antigua and Barbuda ranks 82nd and North Macedonia ranks 82nd of 194 countries.
Antigua and Barbuda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.1% | 0.2% | Antigua and Barbuda |
| 2020s | 0.2% | 0.1% | 0.1% | Antigua and Barbuda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Antigua and Barbuda or North Macedonia?
- Antigua and Barbuda, at 0.2% against 0.2% in North Macedonia as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Antigua and Barbuda and North Macedonia?
- 0.0%, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and North Macedonia?
- 10 years are reported by both, from 2015 to 2024.
- How do Antigua and Barbuda and North Macedonia rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Antigua and Barbuda ranks 82nd and North Macedonia ranks 82nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.